5-methyl-N-[6-chloro-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-pyridine sulfonamide | 179400-97-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-methyl-N-[6-chloro-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-pyridine sulfonamide
• 英文别名: N-[6-chloro-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]-5-methylpyridine-2-sulfonamide
• CAS: 179400-97-6
• 化学式: C₂₁H₁₇ClN₆O₄S
• 分子量: 484.923
• InChiKey: HTJTYKJWHYMDSE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  33
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  138
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  5-methyl-N-[6-chloro-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-pyridine sulfonamide 生成 5-methyl-N-[6-(4-hydroxy-2-butynyloxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-pyridine sulfonamide
  参考文献：
  名称：

  Butyne diol derivatives

  摘要：

  本发明涉及一般式I的新型丁炔二醇衍生物及其在制备药物组合物中作为活性成分的用途。该发明还涉及相关方面，包括制备化合物的过程、含有一种或多种一般式I化合物的药物组合物，特别是它们作为内皮素受体拮抗剂的用途。

  公开号：

  US20030087920A1
• 作为产物：
  描述：

  4,6-二羟基-5-(2-甲氧基苯氧基)-2-(2-嘧啶基)嘧啶 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 以 二甲基亚砜 为溶剂， 生成 5-methyl-N-[6-chloro-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2-pyridine sulfonamide
  参考文献：
  名称：

  掺入不饱和侧链的磺酰胺基嘧啶作为内皮素受体拮抗剂的用途。

  摘要：

  研究了一系列与波生丹1结构相关的化合物，这些化合物在嘧啶核的6位上具有不饱和侧链，具有阻断ET（A）和ET（B）受体的潜力。掺入带有吡啶基氨基甲酰基部分的2-丁炔-1，4-二醇接头导致体外高效的内皮素受体拮抗剂（例如70和75）。在高血压盐敏感性Dahl大鼠的体内模型研究中，炔丙基衍生物26显着降低了血压。

  DOI：

  10.1016/s0960-894x(02)01084-3

文献信息

• BUTYNE DIOL DERIVATIVES
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1244637A1

  公开（公告）日：2002-10-02
• US6720322B2
  申请人：——

  公开号：US6720322B2

  公开（公告）日：2004-04-13
• [EN] BUTYNE DIOL DERIVATIVES<br/>[FR] DERIVES DE BUTYNEDIOL
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2001046156A1

  公开（公告）日：2001-06-28

  The present invention relates to novel butyne diol derivatives ofgeneral formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula (I) and especially their use as endothelin receptor antagonists.
• [EN] PYRIMIDINE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY<br/>[FR] PYRIMIDINE-SULFONAMIDES AGISSANT COMME ANTAGONISTES DE L'ENDOTHELINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2001081335A1

  公开（公告）日：2001-11-01

  The invention relates to novel tetra-substituted pyrimidines and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as endothelin receptor antagonists. The compounds are represented by the general formula (I).
• [EN] SUBSTITUTED SULFONYLAMINOPYRIMIDINES<br/>[FR] SULFONYLAMINOPYRIMIDINES SUBSTITUEES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2001081338A1

  公开（公告）日：2001-11-01

  The present invention relates to novel substituted pyrimidines of the general formula I and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the general formula (I) and especially their use as endothelin receptor antagonists.